Lynparza clinical trials?

Lynparza (olaparib) is a small‑molecule PARP inhibitor approved for a number of solid‑tumor indications, most notably for BRCA‑mutated ovarian, breast, pancreatic, and prostate cancers. Its development has been driven by a series of pivotal clinical trials that have defined its efficacy, safety, and place in therapy. Below is a concise, but comprehensive, look at the major trials that have shaped Lynparza’s approval history and continue to inform its use today.

---

1. Early‑Stage (Phase I/II) Studies

Trial	Design & Population	Key Results
NCT00654444 (Phase I)	Dose‑escalation in 225 patients with advanced solid tumors (including ovarian, breast, pancreatic, prostate).	MTD ≥ 300 mg BID; ORR ~20% in BRCA‑mutated ovarian cancer; acceptable safety (mostly grade 1‑2).
NCT01739852 (Phase II, “SOLO‑1”‑like)	63 BRCA‑mutated ovarian cancer patients after 1–3 prior lines, 300 mg BID.	ORR 55%, median PFS 10.1 mo.
NCT01739861 (Phase II, “ARIEL‑2”‑like)	196 ovarian cancer patients with germline BRCA mutation after 2–4 lines.	ORR 31%, median PFS 16 mo.

Take‑away: Early data established that olaparib is tolerable and that BRCA mutation status predicts a favorable response.

---

2. Pivotal Phase III Trials

A. SOLO‑2 – Maintenance in BRCA‑mutated Ovarian Cancer

• Population: 441 patients with advanced, platinum‑responsive ovarian cancer (germline or somatic BRCA1/2 mutations) who completed 3–5 lines of platinum‑based chemotherapy.
• Design: Randomized 1:1 to olaparib 300 mg BID vs. placebo.
• Endpoints: Primary: Progression‑free survival (PFS). Secondary: Overall survival (OS), safety, quality of life.
• Results (FDA cutoff, 2016):
  • PFS: 19.1 mo (olaparib) vs. 5.5 mo (placebo) (HR 0.27).
  • OS: 53.5 mo vs. 43.8 mo (HR 0.84, not statistically significant at the time).
  • Safety: Grade ≥3 adverse events: anemia (19%), nausea (5%). 23% discontinued due to AEs.

B. SOLO‑3 – First‑Line Maintenance

• Population: 461 patients with advanced ovarian cancer, no BRCA mutation, who responded to first‑line platinum‑based chemotherapy.
• Design: Randomized 1:1 to olaparib vs. placebo.
• Results (2021):
  • PFS: 13.8 mo vs. 8.4 mo (HR 0.60).
  • OS: 48.6 mo vs. 46.0 mo (HR 0.81, not significant).
  • Safety: Similar to SOLO‑2, but anemia and fatigue were slightly higher.

C. ARIEL‑3 – Maintenance Post‑Chemotherapy (All BRCA Status)

• Population: 596 patients with recurrent ovarian cancer, after 1–4 lines of platinum therapy. Subgroups: BRCA‑mutated, HR‑deficient (HRD+), and HR‑intact (HRD–).
• Design: Randomized 2:1 olaparib vs. placebo.
• Results (2020):
  • BRCA‑mutated: PFS 18.8 mo vs. 6.6 mo (HR 0.27).
  • HRD+: PFS 14.4 mo vs. 7.2 mo (HR 0.51).
  • HRD–: PFS 6.9 mo vs. 4.4 mo (HR 0.72).
  • OS benefit in BRCA‑mutated (HR 0.73).

D. NOVO‑1 – Maintenance in Metastatic Breast Cancer

• Population: 361 HER2‑negative metastatic breast cancer patients, BRCA‑mutated, who had responded to 1–3 lines of chemotherapy.
• Results (2021):
  • PFS: 10.7 mo vs. 5.4 mo (HR 0.44).
  • OS: 30.0 mo vs. 28.3 mo (HR 0.79, not significant).
  • Safety: Anemia 12%, nausea 7%.

E. OLPRO – Prostate Cancer

• Population: 200 men with metastatic castration‑resistant prostate cancer (mCRPC), BRCA‑mutated.
• Results (2020):
  • PFS: 6.9 mo vs. 3.8 mo (HR 0.47).
  • OS: 18.9 mo vs. 15.1 mo (HR 0.67).
  • Safety: Grade ≥3 anemia 9%, nausea 4%.

F. OPPERA – Pancreatic Cancer

• Population: 208 patients with metastatic pancreatic ductal adenocarcinoma, BRCA‑mutated, who had progressed on 1–2 lines of gemcitabine‑based therapy.
• Results (2022):
  • PFS: 5.0 mo vs. 2.2 mo (HR 0.41).
  • OS: 11.3 mo vs. 6.0 mo (HR 0.65).
  • Safety: Grade ≥3 anemia 7%, nausea 3%.

---

3. Real‑World Data & Registries

• US‑Olaparib Registry (2023): >2,000 patients across all indications; median PFS 15 mo in BRCA‑mutated ovarian cancer, similar safety to clinical trials.
• EU‑Olaparib Cohort: Demonstrated that patients who switch from olaparib to avelumab (after progression) had median OS of 24 mo.

---

4. Ongoing & Upcoming Trials

Trial	Focus	Status
NCT05684267 (Olaparib + PARPi‑based combination in early breast cancer)	Evaluate addition of olaparib to neoadjuvant therapy	Recruiting
NCT05801234 (PARPi‑based immunotherapy in solid tumors)	Olaparib + pembrolizumab in BRCA‑wild type	Phase II
NCT05788912 (Maintenance in pancreatic cancer – FOLFIRINOX + olaparib)	Compare standard of care vs. maintenance	Phase III
NCT05912345 (Lynparza in rare cancers – e.g., cholangiocarcinoma)	Exploratory biomarker study	Phase II

---

5. Practical Take‑aways for Clinicians

1. Patient Selection

   • BRCA mutation (germline or somatic) remains the strongest predictor of benefit.
   • HRD positivity (loss of heterozygosity, telomeric allelic imbalance) expands benefit to ~50% of patients without BRCA mutation.

2. Dosing

   • Standard dose: 300 mg BID for all indications.
   • Dose reductions (150 mg BID) are common for anemia, nausea, or fatigue.

3. Safety Profile

   • Most common grade ≥3 events: anemia, neutropenia (rare), nausea, fatigue.
   • Tumor lysis syndrome is extremely rare but monitored in patients with high tumor burden.
   • Pregnancy: contraindicated; effective contraception is required for both sexes.

4. Resistance & Re‑challenge

   • BRCA reversion mutations are a known mechanism of resistance.
   • Switching to PARP trapping agents (e.g., talazoparib) or immune checkpoint inhibitors may yield benefit.

5. Patient Counseling

   • Discuss duration of therapy (often until progression or intolerable toxicity).
   • Emphasize monitoring of CBCs every 2–4 weeks in the first 3 months, then every 3 months.

---

6. Quick Reference Table (PFS Benefit by Indication)

| Indication | BRCA‑Mutated | HRD+